A method for determining the infectivity of a virus
The described method addresses the inefficiencies of existing dengue virus infectivity and titer determination by using a serial dilution and immunoassay approach with specific antibodies, enhancing accuracy and throughput while reducing costs.
Patent Information
- Authority / Receiving Office
- US · United States
- Patent Type
- Applications(United States)
- Current Assignee / Owner
- TAKEDA VACCINES INC
- Filing Date
- 2023-11-01
- Publication Date
- 2026-06-18
AI Technical Summary
Current methods for determining the infectivity and titer of dengue virus serotypes are laborious, prone to operator bias, have low throughput, and require expensive equipment, while existing antibodies lack sufficient binding affinity and neutralizing activity.
A method involving serial dilution of virus-containing samples, cell culture, and immunoassay to determine virus antigen presence/amount, using specific antibodies with high binding affinity and neutralizing activity, and a kit comprising primary, secondary, and tertiary antibodies for accurate infectivity assessment.
The method provides a faster, less error-prone, and more cost-effective way to assess infectivity and titer, with higher throughput and sensitivity, suitable for multiplex formats, and allows for precise determination of infectious virus particles.
Smart Images
Figure US20260167703A1-D00000_ABST